Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emanuel Krebs

Showing results (1-10 of 59) with videos related to

Pageof 6
Sort By:
Current HIV/AIDS Reports|March 20, 2021
Cost-Effectiveness Analysis in Implementation Science: a Research Agenda and Call for Wider ApplicationEmanuel Krebs, Bohdan Nosyk
Journal of Acquired Immune Deficiency Syndromes (1999)|September 12, 2022
ReplyBohdan Nosyk, Xiao Zang, Emanuel Krebs
Health Services Research|September 3, 2024
Addressing immortal time bias in precision medicine: Practical guidance and methods developmentDeirdre Weymann, Emanuel Krebs, Dean A Regier
HIV Specialist|May 6, 2020
The impact of localized implementation: determining the cost-effectiveness of HIV prevention and care interventions across six United States citiesEmanuel Krebs, Laura M Dale, Nosyk B
Journal of Substance Abuse Treatment|June 15, 2016
Characterizing Long-Term Health Related Quality of Life Trajectories of Individuals With Opioid Use DisorderEmanuel Krebs, Thomas Kerr, Evan Wood, et al.
Frontiers in Medicine|September 18, 2025
How life-cycle real-world evidence can bridge evidentiary gaps in precision oncologyEmanuel Krebs, Deirdre Weymann, Tania Bubela, et al.
Drug and Alcohol Dependence|October 6, 2014
Dynamics in the costs of criminality among opioid dependent individualsEmanuel Krebs, Thomas Kerr, Julio Montaner, et al.
International Journal of Technology Assessment in Health Care|June 24, 2025
Adopting life-cycle HTA: a tumor-agnostic precision oncology index economic evaluation from publicly available reimbursement reviewsGemma Cupples, Emanuel Krebs, Deirdre Weymann, et al.
Frontiers in Medicine|April 4, 2025
Putting the substance in substantial evidence: an evidence-based approach to flexible drug regulationEmanuel Krebs, Tania Bubela, Melanie McPhail, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 5, 2023
Toward Best Practices for Economic Evaluations of Tumor-Agnostic Therapies: A Review of Current Barriers and SolutionsDeirdre Weymann, Samantha Pollard, Halina Lam, et al.
Pageof 6

Showing results (1-10 of 59) with videos related to

Sort By:
Pageof 6
Current HIV/AIDS Reports|March 20, 2021
Cost-Effectiveness Analysis in Implementation Science: a Research Agenda and Call for Wider ApplicationEmanuel Krebs, Bohdan Nosyk
Journal of Acquired Immune Deficiency Syndromes (1999)|September 12, 2022
ReplyBohdan Nosyk, Xiao Zang, Emanuel Krebs
Health Services Research|September 3, 2024
Addressing immortal time bias in precision medicine: Practical guidance and methods developmentDeirdre Weymann, Emanuel Krebs, Dean A Regier
HIV Specialist|May 6, 2020
The impact of localized implementation: determining the cost-effectiveness of HIV prevention and care interventions across six United States citiesEmanuel Krebs, Laura M Dale, Nosyk B
Journal of Substance Abuse Treatment|June 15, 2016
Characterizing Long-Term Health Related Quality of Life Trajectories of Individuals With Opioid Use DisorderEmanuel Krebs, Thomas Kerr, Evan Wood, et al.
Frontiers in Medicine|September 18, 2025
How life-cycle real-world evidence can bridge evidentiary gaps in precision oncologyEmanuel Krebs, Deirdre Weymann, Tania Bubela, et al.
Drug and Alcohol Dependence|October 6, 2014
Dynamics in the costs of criminality among opioid dependent individualsEmanuel Krebs, Thomas Kerr, Julio Montaner, et al.
International Journal of Technology Assessment in Health Care|June 24, 2025
Adopting life-cycle HTA: a tumor-agnostic precision oncology index economic evaluation from publicly available reimbursement reviewsGemma Cupples, Emanuel Krebs, Deirdre Weymann, et al.
Frontiers in Medicine|April 4, 2025
Putting the substance in substantial evidence: an evidence-based approach to flexible drug regulationEmanuel Krebs, Tania Bubela, Melanie McPhail, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 5, 2023
Toward Best Practices for Economic Evaluations of Tumor-Agnostic Therapies: A Review of Current Barriers and SolutionsDeirdre Weymann, Samantha Pollard, Halina Lam, et al.
Pageof 6